AbbVie Already Dividend King? Why Apogee Deal Could Cement a Dynasty
AbbVie has quietly built a credible dividend track record since its 2013 spin-off from Abbott. The $10.9B Apogee deal...
If you’re new to crypto, you’ll want a clear starting point and safe approach. This intro explains which crypto to buy first and how to assess risk without overwhelming you.
27,491 articlesAbbVie has quietly built a credible dividend track record since its 2013 spin-off from Abbott. The $10.9B Apogee deal...
A retiree with a $600,000 IRA defers claiming Social Security to age 70 to secure the 8% yearly boost. The strategy, ...
In 2026, a single social post can alter a star’s contract. Stay silent, and you risk backlash; speak up, and you may ...
A simple, low-cost two-fund approach using Vanguard MID- and SMALL-CAP ETFs may offer upside versus the S&P 500 over ...
A fiery address from Palantir’s CEO has ignited a broader debate on how AI firms partner with the Pentagon and how po...
Rising tensions over the Strait of Hormuz have sparked volatile moves in oil and equity markets as U.S. intelligence ...
A January 12, 2026 bill aims to ban lawmakers and families from buying stocks, with public notice and hefty penalties...
Gartner CEO Gene Hall tells investors the benefits from recent product and engagement upgrades will appear gradually ...
Commercial Metals posted a blowout quarter in Q2 2026, with revenue hitting $2.132 billion and net income of $93 mill...
Investors weigh income reliability and risk as markets shift. A $1.5 million portfolio that pays roughly $83,400 annu...
Cisco surged about 17% after a record Q3 and stronger AI infrastructure orders, signaling a clear outperformance of p...
A key downgrade and a rival upgrade have split the investor view on CrowdStrike, shifting focus to the Mythos cycle a...